Products
Online Inquiry
ZM-447439
Cat. No.:
0225LY-0667
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
ZM 447439 is an ATP-competitive inhibitor of Aurora A and B (IC50: 110/130 nM) that shows 8-fold greater selectivity over Src and MEK1 and has minimal impact on CDK and Plk1 kinases.
Synonym:
331771-20-1; N-(4-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)phenyl)benzamide; N-[4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl}amino)phenyl]benzamide; N-[4-[[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino]phenyl]benzamide; Benzamide, N-(4-((6-methoxy-7-(3-(4-morpholinyl)propoxy)-4-quinazolinyl)amino)phenyl)-; N-(4-{[6-Methoxy-7-(3-Morpholin-4-Ylpropoxy)quinazolin-4-Yl]amino}phenyl)benzamide
CAS No.:
331771-20-1
Compound CID:
9914412
Formula:
C29H31N5O4
Formula Weight:
513.59
Specification
Targets&IC50:
Aurora B: 130 nM; Aurora A: 110 nM
Relative Density:
1.282 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
ZM-447439 can be used in cell cycle research to study the disruption of chromosome segregation via Aurora B inhibition.
Library Information
Target:
MEK; Src; Aurora kinase
Receptor:
Aurora A; Aurora B; Lck; MEK1; Src
Pathways:
MAPK; Cell cycle/Checkpoint; Angiogenesis; Tyrosine kinase/adaptors; Apoptosis; Chromatin/Epigenetic
Plate Number:
AOCL-9
Plate Location:
f4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
16.7 mg/mL; 32.52 mM
